All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-HIV-1 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target HIV-1. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-HIV-1 antibody linked to CD3ζ signaling domains. And the vector product was designed for the treatment of HIV-1 infection.
CAR Construction : 10E8-41BB-CD3ζ Fig.1 Proliferation mediated by novel CAR interactions with HIV-1-infected target cells. Primary CD8+ T lymphocytes transduced with CARs were enriched to>90% purity and labeled with CellTrace Violet and then cocultured with irradiated HIV-1 NL4-3-infected T2 cells. Ali, A., Kitchen, S. G., Chen, I. S., Ng, H. L., Zack, J. A., & Yang, O. O. (2016). HIV-1-specific chimeric antigen receptors based on broadly neutralizing antibodies. Journal of virology, 90(15), 6999-7006. |
CAR Construction : 10E8-41BB-CD3ζ Fig.2 Specific killing of HIV-1-infected target cells mediated by novel CARs. CAR-transduced primary CD8+ T lymphocytes were cocultured with HIV-1-infected T2 cells in standard 4-h chromium release assays to assess killing mediated by the CARs. Ali, A., Kitchen, S. G., Chen, I. S., Ng, H. L., Zack, J. A., & Yang, O. O. (2016). HIV-1-specific chimeric antigen receptors based on broadly neutralizing antibodies. Journal of virology, 90(15), 6999-7006. |
CAR Construction : 10E8-41BB-CD3ζ Fig.3 Sample calculation of percent log efficiency of suppression by CAR-transduced cells. T1-CCR5 cells were infected with the indicated viruses at a multiplicity of infection of 0.1 tissue culture infective doses cell and cultured with or without CAR 10E8-transduced CD8+ T cells (>90% enriched) at an effector-to-target cell ratio of 1:4. Ali, A., Kitchen, S. G., Chen, I. S., Ng, H. L., Zack, J. A., & Yang, O. O. (2016). HIV-1-specific chimeric antigen receptors based on broadly neutralizing antibodies. Journal of virology, 90(15), 6999-7006. |
CAR Construction : Fig.4 SPR for binding analysis. Kinetic binding analysis revealed that the mature 10E8 binding to the HIV gp41 MPER peptide showed strong binding with decreasing off-rates. Soto, C., Ofek, G., Joyce, M. G., Zhang, B., McKee, K., Longo, N. S., ... & Kwong, P. D. (2016). Developmental pathway of the MPER-directed HIV-1-neutralizing antibody 10E8. PloS one, 11(6), e0157409. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-HIV-1 (10E8) h(CD3ζ) CAR, pCDCAR1 (CAR-MZ210). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION